New York, February 13, 2026, 19:17 EST — After-hours
- OCUL slipped roughly 2% during the session, then surged higher after the bell.
- Ocular Therapeutix is set to host a webcast on Feb. 17, where it plans to present topline Phase 3 SOL-1 results in wet AMD.
- Traders are bracing for a late-stage readout—a binary event that could shake up the stock.
Shares of Ocular Therapeutix surged roughly 25% in after-hours trading Friday, as the company announced when it will reveal topline data from its late-stage wet age-related macular degeneration trial. The stock closed the regular session at $8.88, down 1.9%, but was most recently up 25.2% to $11.12. 1
Bedford, Massachusetts-based Ocular Therapeutix plans to webcast at 8:00 a.m. ET on Tuesday, Feb. 17, with topline readouts from its SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI) in wet AMD on the agenda. Detailed results are set for the Macula Society annual meeting later in the month, running Feb. 25–28. AXPAXLI, an axitinib intravitreal hydrogel, is delivered by injection into the eye using the company’s proprietary bioresorbable hydrogel technology. 2
Timing stands out here. Phase 3 is usually the final major trial ahead of a U.S. approval push, and “topline” refers to that initial read on the main endpoint before all the data goes public.
Here, SOL-1 isn’t just aiming to keep up—it needs to outperform the comparator. So Tuesday’s data drop carries more weight than the typical incremental updates that tend to move shares of smaller biotechs.
It’s also tied to a regulatory filing. The company outlined that SOL-1 pits a single 450-microgram shot of AXPAXLI against one 2 mg injection of aflibercept, with the main focus on vision maintenance at Week 36. There’s a plan to file an NDA for wet AMD after Week 52 data comes in—pending results and discussions with the FDA. That same filing noted the tough competitive field in the U.S., flagging anti-VEGF options already on shelves like Eylea and Eylea HD from Regeneron, plus Genentech’s Lucentis and Vabysmo. 3
Ocular kept the SOL-1 results under wraps on Friday. Traders were simply responding to the timing—there wasn’t any unexpected news dropping.
First up for investors: does the trial hit its primary vision goal? They’ll also be poring over the topline data for any signals on durability—basically, how long patients stay off further treatment—and digging into the safety numbers.
Repeated injections targeting VEGF—key in abnormal blood vessel growth—remain the go-to for wet AMD. But there’s a push for new methods that ease the treatment load while preserving vision improvements.
But this stock’s gains can vanish just as quickly. If the primary endpoint isn’t met, or if durability falls short, or safety flags pop up, the after-hours rally could disappear. Even with a “positive” result, questions about labeling and dosing intervals may linger when regulators get the complete data.
U.S. equity markets are shut Monday for Presidents Day, so regular trading resumes Tuesday, just as Ocular’s webcast kicks off at 8:00 a.m. That means the SOL-1 data drops right as the first trades of the week hit the tape. 4
